Advisors Asset Management Inc. Has $2.62 Million Stake in Vertex Pharmaceuticals Incorporated (VRTX)

Advisors Asset Management Inc. raised its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 21.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,434 shares of the pharmaceutical company’s stock after acquiring an additional 2,694 shares during the quarter. Advisors Asset Management Inc.’s holdings in Vertex Pharmaceuticals were worth $2,623,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the company. HighPoint Advisor Group LLC purchased a new position in shares of Vertex Pharmaceuticals during the 2nd quarter valued at $864,000. Schroder Investment Management Group lifted its stake in shares of Vertex Pharmaceuticals by 7.3% during the 2nd quarter. Schroder Investment Management Group now owns 27,309 shares of the pharmaceutical company’s stock valued at $4,031,000 after buying an additional 1,849 shares in the last quarter. Senator Investment Group LP lifted its stake in shares of Vertex Pharmaceuticals by 80.2% during the 2nd quarter. Senator Investment Group LP now owns 720,000 shares of the pharmaceutical company’s stock valued at $122,371,000 after buying an additional 320,483 shares in the last quarter. Verition Fund Management LLC purchased a new position in shares of Vertex Pharmaceuticals during the 2nd quarter valued at $1,341,000. Finally, Morse Asset Management Inc lifted its stake in shares of Vertex Pharmaceuticals by 12.6% during the 2nd quarter. Morse Asset Management Inc now owns 6,051 shares of the pharmaceutical company’s stock valued at $1,028,000 after buying an additional 675 shares in the last quarter. Institutional investors and hedge funds own 93.54% of the company’s stock.

In other news, EVP Stuart A. Arbuckle sold 10,083 shares of the business’s stock in a transaction dated Friday, August 3rd. The shares were sold at an average price of $175.29, for a total value of $1,767,449.07. Following the sale, the executive vice president now directly owns 48,877 shares in the company, valued at approximately $8,567,649.33. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Michael Parini sold 2,125 shares of the business’s stock in a transaction dated Friday, October 12th. The stock was sold at an average price of $177.20, for a total transaction of $376,550.00. Following the completion of the sale, the executive vice president now owns 41,734 shares in the company, valued at $7,395,264.80. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 33,325 shares of company stock worth $6,135,340. Insiders own 0.75% of the company’s stock.



Shares of VRTX stock opened at $169.48 on Friday. Vertex Pharmaceuticals Incorporated has a 52 week low of $136.50 and a 52 week high of $194.92. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.55 and a current ratio of 3.67. The firm has a market capitalization of $45.34 billion, a price-to-earnings ratio of 211.85, a P/E/G ratio of 1.79 and a beta of 1.48.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Wednesday, October 24th. The pharmaceutical company reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.07. Vertex Pharmaceuticals had a net margin of 15.84% and a return on equity of 19.86%. The firm had revenue of $784.54 million for the quarter, compared to the consensus estimate of $782.95 million. During the same period in the previous year, the firm posted $0.53 EPS. As a group, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 2.51 earnings per share for the current fiscal year.

VRTX has been the topic of a number of analyst reports. Zacks Investment Research upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $178.00 target price on the stock in a research note on Saturday, June 30th. Cantor Fitzgerald began coverage on shares of Vertex Pharmaceuticals in a research note on Monday, October 1st. They issued an “overweight” rating and a $217.00 price target on the stock. Piper Jaffray Companies decreased their price target on shares of Vertex Pharmaceuticals to $217.00 and set an “overweight” rating on the stock in a research note on Friday. Argus boosted their price target on shares of Vertex Pharmaceuticals to $200.00 and gave the stock an “average” rating in a research note on Tuesday, August 28th. They noted that the move was a valuation call. Finally, Citigroup boosted their price target on shares of Vertex Pharmaceuticals from $203.00 to $206.00 and gave the stock a “buy” rating in a research note on Monday, July 30th. Three investment analysts have rated the stock with a hold rating, twenty-three have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $201.83.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.

Featured Story: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply